{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-012131","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.406898+00:00","generated_at":"2026-06-03T22:17:04.186237+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Monopar files provisional patent for MNPR-101 radiopharma optimization findings","bullets":["Filed provisional patent 'Antibody Radioisotope Constructs' covering MNPR-101-Zr construct, including radioisotope, linker, and antibody variations.","Patent aims to protect stability and biodistribution properties of MNPR-101-Zr.","MNPR-101-Zr is a zirconium-89 imaging version of Monopar's anti-uPAR antibody for advanced cancers.","Filing strengthens IP for MNPR-101 radiopharma program; Phase 1 dosimetry trial recently initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-012131","json":"https://secwatch.observer/filing/0001437749-24-012131.json","markdown":"https://secwatch.observer/filing/0001437749-24-012131.md","text":"https://secwatch.observer/filing/0001437749-24-012131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924012131/0001437749-24-012131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924012131/mnpr20240415_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:17:04.186237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}